Inhibrx Biosciences, Inc. (INBX)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Inhibrx Biosciences Secures Bristol Myers Squibb Deal for Cancer Drug INBRX-109
# 🧾 What This Document Is This is an Annual Report to Security Holders (ARS). It's a company's "year in review" book sent to shareholders, combining the formal annual report (10-K) with shareholder-friendly visuals, letters, and business highlights. Think of it as the company's curated, investor-fo
INBX Sets June 3 Annual Meeting to Elect Directors Ratify Auditors
# 🧾 What This Document Is This is a **DEF 14A**, also called a **proxy statement**. Think of it as an invitation and information packet for the company's annual shareholder meeting. It explains what will be voted on, who is running the company, and how much the top executives are paid. Shareholders
INBX Ozekibart achieves 20% ORR in CRC and doubles PFS in chondrosarcoma
# 📰 What This Document Is 📄 This 8-K filing is a Current Report, meaning Inhibrx Biosciences is providing an immediate, detailed update to the public about major developments, specifically clinical trial data. Since the company is developing complex biologics, investors need to know about the prog
SEC filings
All filings →Insider trades
All insider trades →Inhibrx Biosciences, Inc. has no reported insider trades in the last 90 days.